Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C

World Journal of Gastroenterology

Volumn 15, Issue 3, 2009, Pages 328-333

  Gelu Simeon, Moana ^a   Burlaud, Aurore ^a   Young, Jacques ^a   Pelletier, Gilles ^a   Buffet, Catherine ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Chronic hepatitis C; Interferon alpha; Predictive factors; Thyroid disorder

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBROSIS; FOLLOW UP; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; THYROID DISEASE; THYROID FUNCTION;

EID: 59249092117     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.328     Document Type: Article

References (22)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
3. Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002; 26 Spec No 2: B303-B320
4. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni PL, Colombo M, Beck-Peccoz P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132: 587-593
5. Benelhadj S, Marcellin P, Castelnau C, Colas-Linhart N, Benhamou JP, Erlinger S, Bok B. Incidence of dysthyroidism during interferon therapy in chronic hepatitis C. Horm Res 1997; 48: 209-214
6. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C, Sorvillo F, Caporaso N, Amato G. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001; 86: 1925-1929
7. Dalgard O, Bjoro K, Hellum K, Myrvang B, Bjoro T, Haug E, Bell H. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002; 251: 400-406
8. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, Garcia-Monzon C, Arranz A, Borque MJ, Moreno-Otero R. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996; 44: 635-642
9. Mekkakia-Benhabib C, Marcellin P, Colas-Linhart N, Castel-Nau C, Buyck D, Erlinger S, Bok B. [Natural history of dysthyroidism during interferon treatment of chronic hepatitis C] Ann Endocrinol (Paris) 1996; 57: 419-427
10. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Neri TM, Braverman LE. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996; 101: 482-487
11. Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, Lin ZY, Hsieh MY, Liu JF, Wang LY, Chang WY. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000; 142: 431-437
12. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, Salmeron J. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998; 158: 1445-1448
13. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26: 206-210
14. Moncoucy X, Leymarie F, Delemer B, Levy S, BernardChabert B, Bouche O, Jolly D, Diebold MD, Cadiot G, Thiefin G. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 2005; 29: 339-345
15. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293
16. Chedin P, Chanson P, Duranteau L, Guillausseau PJ, Lubetzki J. [Dysthyroidism in patients treated with interferon alpha] Presse Med 1994; 23: 1659-1663
17. Bohbot NL, Young J, Orgiazzi J, Buffet C, Francois M, Bernard-Chabert B, Lukas-Croisier C, Delemer B. Interferonalpha- induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease. Eur J Endocrinol 2006; 154: 367-372
18. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006; 43: 661-672
19. Broussolle C, Steineur MP, Bailly F, Zoulim F, Trepo C. [Hepatitis C virus infection and thyroid diseases] Rev Med Interne 1999; 20: 766-773
20. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004; 89: 3656-3661
21. Kabbaj N, Guedira MM, El Atmani H, El Alaoui M, Mohammadi M, Benabed K, Lachkar H, Benaissa A. Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Ann Endocrinol (Paris) 2006; 67: 343-347
22. Kee KM, Lee CM, Wang JH, Tung HD, Changchien CS, Lu SN, Wang PW. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol 2006; 21: 319-326